Tango Therapeutics, Inc. Earnings Dividend

Tango Therapeutics, Inc.’s revenue fell -100% since last year same period to $0Mn in the Q1 2026. On a quarterly growth basis, Tango Therapeutics, Inc. has generated NaN% jump in its revenue since last 3-months.

Tango Therapeutics, Inc.’s net profit fell -14.14% since last year same period to $-45.51Mn in the Q1 2026. On a quarterly growth basis, Tango Therapeutics, Inc. has generated -17.46% fall in its net profits since last 3-months.

Tango Therapeutics, Inc.’s net profit margin fell -Inf% since last year same period to -Inf% in the Q1 2026. On a quarterly growth basis, Tango Therapeutics, Inc. has generated NaN% jump in its net profit margins since last 3-months.

Tango Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.3 - a 6.99% jump from last quarter’s estimates.

Tango Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.3.

Tango Therapeutics, Inc.’s earning per share (EPS) jumped 11.11% since last year same period to -0.32 in the Q1 2026. This indicates that the Tango Therapeutics, Inc. has generated 11.11% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Tango Therapeutics, Inc.’s return on assets (ROA) stands at -0.21.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Tango Therapeutics, Inc.’s return on equity (ROE) stands at -0.38.